Allosterism in the adenosine A 2A and cannabinoid CB 2 heteromer
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.16502 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Claudia Llinas Del Torrent und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain. Hauptthemen laut MEDLINE: Receptor, Adenosine A2A, Receptor, Cannabinoid, CB2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Spanish Ministry of Economy and Innovation, Generalitat de Catalunya, FPI fellowship.
Abstract (Originalsprache)
Background and Purpose Allosterism is a regulatory mechanism for GPCRs that can be attained by ligand‐binding or protein–protein interactions with another GPCR. We have studied the influence of the dimer interface on the allosteric properties of the A 2A receptor and CB 2 receptor heteromer. Experimental Approach We have evaluated cAMP production, phosphorylation of signal‐regulated kinases (pERK1/2), label‐free dynamic mass redistribution, β‐arrestin 2 recruitment and bimolecular fluorescence complementation assays in the absence and presence of synthetic peptides that disrupt the formation of the heteromer. Molecular dynamic simulations provided converging evidence that the heteromeric interface influences the allosteric properties of the A 2A R–CB 2 R heteromer. Key Results Apo A 2A R blocks agonist‐induced signalling of CB 2 R. The disruptive peptides, with the amino acid sequence of transmembrane (TM) 6 of A 2A R or CB 2 R, facilitate CB 2 R activation, suggesting that A 2A R allosterically prevents the outward movement of TM 6 of CB 2 R for G protein binding. Significantly, binding of the selective antagonist SCH 58261 to A 2A R also facilitated agonist‐induced activation of CB 2 R. Conclusions and Implications It is proposed that the A 2A R–CB 2 R heteromer contains distinct dimerization interfaces that govern its functional properties. The molecular interface between protomers of the A 2A R–CB 2 R heteromer interconverted from TM 6 for apo or agonist‐bound A 2A R, blocking CB 2 R activation, to mainly the TM 1/7 interface for antagonist‐bound A 2A R, facilitating the independent opening of intracellular cavities for G protein binding. These novel results shed light on a different type of allosteric mechanism and extend the repertoire of GPCR heteromer signalling. LINKED ARTICLES This article is part of a themed issue Complexity of GPCR Modulation and Signaling (ERNST). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.14/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain.
- Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.
- Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
- Institute of Neuroscience, University of Barcelona (NeuroUB), Barcelona, Spain.
- Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, Barcelona, Spain.
ORCID-Profile: Claudia Llinas Del Torrent, Rafael Franco, Gemma Navarro
Förderung
- Spanish Ministry of Economy and Innovation
- Generalitat de Catalunya
- FPI fellowship
Zitieren
APA
Llinas Del Torrent, C., Raïch, I., Gonzalez, A., Lillo, J., Casajuana-Martin, N., Franco, R., Pardo, L., & Navarro, G. (2025). Allosterism in the adenosine A 2A and cannabinoid CB 2 heteromer. British Journal of Pharmacology. https://doi.org/10.1111/bph.16502
Vancouver
Llinas Del Torrent C, Raïch I, Gonzalez A, Lillo J, Casajuana-Martin N, Franco R, et al. Allosterism in the adenosine A 2A and cannabinoid CB 2 heteromer. British Journal of Pharmacology. 2025. doi:10.1111/bph.16502
BibTeX
@article{LlinasDelTorrent2025,
author = {Llinas Del Torrent, Claudia and Raïch, Iu and Gonzalez, Angel and Lillo, Jaume and Casajuana-Martin, Nil and Franco, Rafael and Pardo, Leonardo and Navarro, Gemma},
title = {Allosterism in the adenosine A 2A and cannabinoid CB 2 heteromer},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.16502}
}
EUVIMED